MENLO PARK, Calif., Oct. 16 /PRNewswire-FirstCall/ -- XTENT, Inc. today announced that 2-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company’s investigational Custom NX(R) drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation’s (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.
In addition, the company will conduct a number of activities during the meeting including an analyst webcast and teleconference to review the CUSTOM I and CUSTOM II clinical data, an evening drug-eluting stent symposium, and an exhibition at booth 6097 on Level 2 of the Washington Convention Center.
http://investor.xtentinc.com/events.cfmhttp://investor.xtentinc.com
About XTENT
XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT Custom NX DES Systems have not been approved for sale by any regulatory authority.
Information about XTENT is available at our website at http://www.xtentinc.com.
CONTACT: investors, Tim Kahlenberg, Chief Financial Officer of XTENT,
Inc., +1-650-475-9400, tkahlenberg@xtentinc.com; or media relations, Aimee
Corso, +1-310-780-2661, acorso@weisscommpartners.com, for XTENT, Inc.
Web site: http://www.xtentinc.com/
